UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $441
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle has maintained a Buy rating on Madrigal Pharmaceuticals and increased the price target from $411 to $441.
November 01, 2024 | 6:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Eliana Merle has maintained a Buy rating on Madrigal Pharmaceuticals and increased the price target from $411 to $441.
The increase in the price target from $411 to $441 by UBS suggests a positive outlook on Madrigal Pharmaceuticals' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100